Patients with cancer experience many stressors placing them at risk for posttraumatic stress disorder (PTSD) symptoms, yet little is known about factors associated with PTSD symptoms in this population. This study explored relationships among patients' PTSD symptoms, physical and psychological symptom burden, and risk for hospital readmissions. METHODS: We prospectively enrolled patients with cancer admitted for an unplanned hospitalization from August 2015-April 2017. Upon admission, we assessed patients' PTSD symptoms (Primary Care PTSD Screen), as well as physical (Edmonton Symptom Assessment System [ESAS]) and psychological (Patient Health Questionnaire 4 [PHQ-4]) symptoms. We examined associations between PTSD symptoms and patients' physical and psychological symptom burden using linear regression. We evaluated relationships between PTSD symptoms and unplanned hospital readmissions within 90-days using Cox regression. RESULTS: We enrolled 954 of 1,087 (87.8%) patients approached, and 127 (13.3%) screened positive for PTSD symptoms. The 90-day hospital readmission rate was 38.9%. Younger age, female sex, greater comorbidities, and genitourinary cancer type were associated with higher PTSD scores. Patients' PTSD symptoms were associated with physical symptoms (ESAS physical: B 5 3.41; P <.001), the total symptom burden (ESAS total: B 5 5.97; P <.001), depression (PHQ-4 depression: B 5 0.67; P <.001), and anxiety symptoms (PHQ-4 anxiety: B 5 0.71; P <.001). Patients' PTSD symptoms were associated with a lower risk of hospital readmissions (hazard ratio, 0.81; P 5.001). CONCLUSIONS: A high proportion of hospitalized patients with cancer experience PTSD symptoms, which are associated with a greater physical and psychological symptom burden and a lower risk of hospital readmissions. Interventions to address patients' PTSD symptoms are needed and should account for their physical and psychological symptom burden. Cancer
INTRODUCTION
Patients with cancer often experience numerous stressors, including the sudden and unexpected threat of a life-altering illness, uncertainty regarding their future, and a perceived loss of control. [1] [2] [3] In addition, the anticipation of facing the adverse consequences associated with cancer and experiencing debilitating side effects from treatment can have traumatic repercussions for patients. 4, 5 Notably, a cancer diagnosis may embody both external and internal threats, which patients can perceive as inescapable and/or hopeless. 6, 7 Therefore, patients with cancer represent a population uniquely vulnerable to experiencing symptoms of posttraumatic stress disorder (PTSD) or suffering an exacerbation of preexisting PTSD symptoms.
Previous research suggests that a substantial proportion of patients with cancer experience PTSD symptoms. 8 For example, studies involving patients with breast cancer have demonstrated that approximately 10% of patients experience PTSD symptoms, which are associated with worse quality of life. [9] [10] [11] [12] Among patients with hematologic malignancies who undergo stem cell transplantation, studies suggest that more than 20% may report PTSD symptoms, which are associated with worse patient outcomes. 13, 14 However, research is lacking regarding the rates of PTSD symptoms among patients with other types of cancer. In addition, despite evidence linking PTSD symptoms with patients' psychological distress, 8, [14] [15] [16] we lack information regarding associations between PTSD symptoms and patients' physical symptom burden. Moreover, little data currently exist about the relationship between PTSD symptoms and health care utilization, such as hospital readmissions. Importantly, symptom flare-ups and the need for hospital-level care may serve as a reminder of the life-threatening nature of cancer and thus may trigger a traumatic stress response among patients with cancer. 5, 17 Although hospitalized patients with cancer often experience a substantial physical and psychological symptom burden, information about PTSD symptoms among these patients is scarce. 18 Therefore, in the current study, we prospectively collected patients' self-reported PTSD symptoms to better understand the prevalence and associated factors of PTSD symptoms among hospitalized patients with cancer. We also sought to examine relationships between patients' PTSD symptoms and their physical and psychological symptom burden. We hypothesized that patients who experience PTSD symptoms would report a worse physical and psychological symptom burden. In addition, we explored for associations between patients' PTSD symptoms and their health care utilization (ie, unplanned hospital readmissions). By studying the relationships among patients' PTSD symptoms, physical and psychological symptoms, and health care utilization, we sought to understand the importance of PTSD symptoms for patients with cancer.
MATERIALS AND METHODS

Study Procedures
This study was approved by the Dana-Farber/Harvard Cancer Center institutional review board. From August 1, 2015, to April 20, 2017, we enrolled patients with cancer and an unplanned hospital admission at Massachusetts General Hospital into a longitudinal cohort study. We identified and recruited consecutive patients who had an unplanned hospital admission (index hospitalization) during the study period by screening the daily inpatient oncology census. Each participant contributed 1 unique hospitalization. We obtained written informed consent from eligible patients on the first weekday after admission (within 2-5 days of hospitalization). After consent, participants completed a symptom burden questionnaire.
Participants
Patients eligible for study participation included those who were at least 18 years old and had been admitted to Massachusetts General Hospital with a known diagnosis of cancer. Study participants also had to be able to read and respond to study questionnaires in English or with minimal assistance from an interpreter. We excluded patients with elective or planned hospital admissions, which were defined as hospitalizations for chemotherapy administration, scheduled surgical procedures, chemotherapy desensitization, or stem cell transplantation.
Study Measures
Sociodemographic and clinical characteristics
To obtain information about each participant's date of birth, sex, race, relationship status, education, and religion, we reviewed the demographic section of the electronic health record. In addition, we used the electronic health record to review each patient's oncology clinic notes to determine the Charlson Comorbidity Index, the date of the cancer diagnosis, the cancer type, and whether the patient had incurable or curable cancer. We defined patients with incurable cancer as those not being treated with curative intent on the basis of the chemotherapy order entry treatment designation (palliative vs curative) or according to documentation in the oncology clinic notes for those not receiving chemotherapy.
PTSD symptoms
We used the Primary Care PTSD Screen (PC-PTSD), which has been used in both primary care and oncology populations, to assess symptoms of posttraumatic stress. 12, [19] [20] [21] The PC-PTSD is a 4-item screen with a binary (yes or no) response pattern designed to evaluate symptoms of PTSD. 19 We asked patients the following: "When thinking about your illness with cancer, have you ever had any experience that was so frightening, horrible, or upsetting that, in the past month, you . . . a) Have had nightmares about it or thought about it when you did not want to?, b) Tried hard not to think about it or went out of your way to avoid situations that reminded you of it?, c) Were constantly on guard, watchful, or easily startled?, d) Felt numb or detached from others, activities, or your surroundings?" The PC-PTSD screen can be interpreted both continuously and dichotomously: an affirmative response to 3 or more questions generates a score 3, which indicates a positive screen for PTSD symptoms.
Physical and psychological symptom burden
We used the self-administered revised Edmonton Symptom Assessment System (ESAS) to assess patients' symptoms. 22 The revised ESAS assesses pain, fatigue, drowsiness, nausea, appetite, dyspnea, depression, anxiety, and well-being over the previous 24 hours. We also included constipation because this is a highly prevalent symptom among patients with cancer. 23 Each individual symptom is scored on a 0 to 10 scale (0 reflecting an absence of the symptom and 10 reflecting the worst possible severity). We categorized the severity of ESAS scores as Original Article none (0), mild (1-3), moderate (4-6), or severe (7-10) in agreement with prior research. 24 In addition, we computed composite ESAS physical and total symptom variables, which include summated scores of patients' physical (pain, fatigue, drowsiness, nausea, appetite, dyspnea, and constipation) and total symptoms (pain, fatigue, drowsiness, nausea, appetite, dyspnea, depression, anxiety, wellbeing, and constipation). These ESAS physical and total symptom variables are well validated and have been used previously in the oncology setting. 22, 25 We used the Patient Health Questionnaire 4 (PHQ-4) to assess participants' psychological symptoms. 26 The PHQ-4 is a 4-item tool with two 2-item subscales that evaluate depression and anxiety symptoms. Both the subscales and the composite PHQ-4 can be evaluated continuously, with higher scores indicating worse psychological distress. 26 
Health care utilization
We sought to explore the relation between patients' PTSD symptoms and their risk of unplanned hospital readmissions. For this outcome, we used the time to first unplanned hospital readmission within 90 days of hospital discharge. We used the 90-day time frame to account for possible mortality because we recognize that patients who die after their index hospitalization have less time at risk for hospital readmissions. We defined the time to first unplanned hospital readmission as the number of days from hospital discharge to the first unplanned hospital readmission within 90 days. We censored patients without a hospital readmission at their 90-day postdischarge date and those who died within 90 days at their death date.
Statistical Analysis
We used descriptive statistics to evaluate the frequencies, means, and standard deviations (SDs) for participants' characteristics, PTSD symptoms, physical and psychological symptom burden, and health care utilization measures. To explore relationships between participant characteristics and continuous PTSD scores, we used linear regression modeling with purposeful selection of covariates. 27 For purposeful selection, we included covariates that were associated at a significance level < .10 and any confounders (defined as any variable that changed the parameter estimate of another variable by >20% when removed from the model) in the final model. To examine relationships between continuous PTSD symptoms and patients' physical and psychological symptom burden, we used linear regression models adjusted for potential confounders, including age, sex, marital status, education level, comorbidities (Charlson Comorbidity Index), cancer type, presence of incurable cancer, and time since cancer diagnosis. 10, [28] [29] [30] [31] [32] [33] [34] We also used Fisher's exact test to compare the rates of moderate/severe ESAS symptoms for patients with and without a positive screen for PTSD symptoms. To investigate the relationships between continuous PTSD symptoms and time to hospital readmission within 90 days, we used Cox proportional hazards regression models adjusted for potential confounders, including age, sex, marital status, education level, comorbidities, cancer type, presence of incurable cancer, time since cancer diagnosis, length of stay during the index hospital admission, PHQ-4 depression symptoms, PHQ-4 anxiety symptoms, and ESAS physical symptoms. 10, [28] [29] [30] [31] [32] [33] [34] All reported P values are 2-sided, with P < .05 considered statistically significant. We used SPSS for Windows (version 20; SPSS, Chicago, Illinois) for statistical analyses.
RESULTS
Participant Sample
We screened a total of 2610 patients for eligibility (Fig.  1 ). We approached 1087 eligible patients, and 954 participants (87.8%) enrolled and provided data about PTSD symptoms (Fig. 1) . Only 4 participants did not complete the PC-PTSD screen. Participants' mean age was 62.80 6 13.50 years (median age, 65.00 years; interquartile range, 55.00-72.00 years). Participants were primarily white (91.6%), married (63.1%), and educated beyond high school (55.5%; Table 1 ). Gastrointestinal cancers (22.2%), lymphomas (19.0%), and leukemias (16.0%) were the most common cancer types. Participants had a median time since the diagnosis of cancer of 11.79 months (interquartile range, 3.31-41.03 months), and approximately half (49.5%) had incurable cancer. The hospital readmission rate within 90 days was 38.9% in the sample.
PTSD Symptoms
Participants had a mean PC-PTSD score of 0.99 (SD, 1.19), and 13.3% (n 5 127) screened positive for PTSD symptoms. On the individual items, "Tried hard not to think about it or went out of your way to avoid situations that reminded you of it" (30.6%) was most commonly endorsed, and this was followed by "Have had nightmares about it or thought about it when you did not want to" (26.5%), "felt numb or detached" (26.3%), and "constantly on guard, watchful, or easily startled" (15.8% , 0.41; P < .001), the total symptom burden (ESAS total: B 5 5.97; 95% CI, 4.95-7.00; SE, 0.52; P < .001), depression symptoms (PHQ-4 depression: B 5 0.67; 95% CI, 0.58-0.77; SE, 0.05; P < .001), and anxiety symptoms (PHQ-4 anxiety: B 5 0.71; 95% CI, 0.62-0.80; SE, 0.05; P < .001).
As shown in Figure 2 , patients who screened positive for PTSD symptoms had higher rates of a moderate/ severe symptom burden. For example, patients who screened positive for PTSD symptoms had higher rates of moderate/severe fatigue (92.9% vs 82.1%; P 5 .001), drowsiness (83.5% vs 65.3%; P < .001), pain (78.7% vs 59.6%; P < .001), and lack of appetite (73.0% vs 58.6%; P 5 .002).
Relationship Between PTSD Symptoms and Health care Utilization
Patients' PTSD symptoms were associated with a lower risk of unplanned hospital readmissions within 90 days (hazard ratio, 0.81; 95% CI, 0.72-0.91; SE, 0.06; P < .001) in Cox regression models adjusted for age, sex, marital status, education level, comorbidities, cancer type, presence of incurable cancer, time since cancer diagnosis, Original Article length of stay during the index hospital admission, PHQ-4 depression symptoms, PHQ-4 anxiety symptoms, and ESAS physical symptoms.
DISCUSSION
In this prospective study of hospitalized patients with cancer, we demonstrated that a substantial proportion of patients experience PTSD symptoms, and we identified participant characteristics associated with a greater likelihood of experiencing these symptoms. Importantly, we also found that patients' PTSD symptoms were significantly associated not only with their physical and psychological symptom burden but also with their health care utilization. Collectively, these findings provide important new evidence regarding the rates and correlates of PTSD symptoms while also highlighting associations between these symptoms and other important patient outcomes. Our work underscores the remarkably high rates of PTSD symptoms experienced by hospitalized patients with multiple types of cancer. More than 13% of patients met criteria for PTSD symptoms, which is higher than much of the prior work involving patients with cancer, [10] [11] [12] 16, [35] [36] [37] and may be related to the study setting and the fact that we recruited patients with various types of cancer, including hematologic malignancies. A more complete understanding of the frequency and impact of PTSD symptoms among patients with cancer could be instrumental in 1) identifying patients at higher risk for experiencing PTSD symptoms, 2) understanding how PTSD symptoms may influence patient outcomes, and 3) providing additional services targeted at the specific supportive-care needs of these patients. Prior work suggests a relationship between patients' PTSD symptoms and their quality of life, psychological distress, and coping strategies, and thus by not diagnosing and managing PTSD symptoms, we miss an opportunity to enhance important patient outcomes. [9] [10] [11] [12] [13] [14] [15] [16] 38, 39 In addition, by demonstrating the significant associations between PTSD symptoms and patients' physical and psychological symptom burden, our work provides compelling evidence supporting the need for efforts to address PTSD symptoms when seeking to comprehensively manage a patient's symptom burden. To our knowledge, the current study is the first to report that patients' PTSD symptoms are associated with both their physical and psychological symptom burden as well as their health care utilization. Although prior studies have highlighted that PTSD symptoms often correlate with psychological distress in patients with cancer, [14] [15] [16] information about the relationship between PTSD symptoms and patients' physical symptom burden was lacking. Patients' physical symptoms may serve as a reminder of their cancer diagnosis, and in turn, this re-experiencing of symptoms may trigger PTSD symptoms such as intrusive thoughts, distress, and increased arousal. 5, 17, 36, 37 Alternatively, greater endorsement of PTSD symptoms among patients with cancer may indicate a continued preoccupation with the illness and/or hypervigilance regarding physical symptoms as a sign of potential disease recurrence. 17 Interestingly, we found that patients' PTSD symptoms were associated with a lower risk of unplanned hospital readmissions. This finding, although hypothesisgenerating, may be related to the avoidance component of PTSD symptoms 14, 37, 40 because patients may seek to avoid places and circumstances that can arouse recollections of the trauma surrounding their cancer diagnosis. Clinically, the tendency of patients with greater PTSD symptoms to avoid hospitalizations may result in delayed care, and this could also help to explain why these individuals reported a greater physical and psychological symptom burden upon presentation to the hospital. By demonstrating these novel findings regarding the associations among PTSD symptoms, patients' physical and psychological symptom burden, and their health care utilization, we hope to highlight the need to develop interventions tailored to patients with cancer who report PTSD symptoms.
Notably, we identified patient characteristics associated with PTSD symptoms. Consistent with prior studies, younger and female patients had greater PTSD symptoms. 10, 28 Research suggests that younger and female patients with cancer report greater unmet supportive-care needs, and older patients may experience less emotional variation than younger patients. [41] [42] [43] [44] [45] [46] We also demonstrated a relationship between the number of comorbid conditions and greater PTSD symptoms, which may indicate the need to screen for these symptoms among patients with cancer and additional comorbid illnesses. 47 Education level did not correlate with PTSD symptoms in our sample, in contrast to prior work, underscoring the importance of screening for PTSD symptoms, even in highly educated patients.
10,40 Intriguingly, we identified an association between PTSD symptoms and patients with genitourinary cancers. Additional research is warranted to help understand the mechanisms underlying this finding, and investigators should explore whether the types of treatments that patients receive and/or the potential trauma related to the diagnosis and management may play a role. Ultimately, these findings will help to identify individuals at greater risk for PTSD symptoms and should inform future efforts to target these patients with supportive-care interventions to address these symptoms.
This study has several limitations that merit discussion. First, we performed the study at a single tertiary care site in a patient sample with limited socioeconomic diversity, and thus the findings may not be generalizable to more diverse populations or patients in different geographic areas. In addition, most patients who receive their cancer care at our institution are admitted within our health system, and we tracked all hospital readmissions to any hospital within our health system. However, for the few patients who required hospitalization outside our health system, we may be underestimating the readmission risk. We also do not have data on whether patients were discharged to hospice bridge programs, which could affect readmission risk. Second, we lack information about patients' coping strategies, social supports, baseline psychiatric disorders, cognition and delirium, and PTSD before their cancer diagnosis; such factors may affect the risk of PTSD symptoms among patients with cancer. Also, we used a PTSD screening instrument and do not have data on formal diagnostic criteria for PTSD. Third, we investigated associations among PTSD symptoms, symptom burden, and health care utilization in a sample with various cancer types and stages, and thus we cannot comment on causality or determine the mechanisms of these associations. Finally, we obtained information about patients' PTSD symptoms and their physical and psychological symptom burden within 5 days of hospital admission, but we lack information regarding changes in these symptoms over time. Future research should include longitudinal assessments to better understand how patients' PTSD symptoms vary over time and in response to changes in other important factors, such as their physical and psychological symptom burden.
Our study provides innovative findings regarding the rates and correlates of PTSD symptoms among patients with cancer. In addition, by demonstrating associations between patients' PTSD symptoms and greater physical and psychological symptom burden, we highlight the importance of addressing PTSD symptoms in this highly symptomatic population. Notably, the relationship that we discovered between patients' PTSD symptoms and a lower risk of unplanned hospital readmissions underscores the need for investigators to study how PTSD symptoms may influence patients' decision about when to pursue hospital-level care. Future research should focus on developing and testing interventions to address patients' PTSD symptoms in addition to their physical and psychological symptom burden while empowering them to seek help appropriately and use health care services when needed.
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